Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria Common to Both Part A:~* Participant must have active plaque psoriasis covering at least 10% body surface area and a PASI score of at least 12 at screening and at randomization.~* Participant is a candidate for systemic therapy~* Participant has a Static Physician's Global Assessment (sPGA) score of at least 3 at screening and at randomization~Inclusion Criterion Specific to Part B~* Participant has completed the treatment period for part A (at least through week 20)~Inclusion Criterion Specific to Part C~* Participant has completed the treatment period for part B~Exclusion Criteria Common to Part A, B and C:~* Participant has pustular, erythrodermic and/or guttate forms of psoriasis~* Participant has had a clinically significant flare of psoriasis during the 12 weeks prior to study entry~* Participant has recently used any biologic agent/monoclonal antibody within the following washout periods: etanercept \>28 days, infliximab or adalimumab \>56 days, alefacept \>60 days, ustekinumab \>8 months, or any other biologic agent/monoclonal antibody \>5 half-lives prior to baseline~* Participant has received systemic psoriasis therapy (such as psoralen and ultraviolet A \[PUVA\] light therapy, cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, azathioprine) or phototherapy (including ultraviolet B or self-treatment with tanning beds) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization (exception: class 6 \[mild, such as desonide\] or 7 \[least potent, such as hydrocortisone\] topical steroids will be permitted for use limited to the face, axilla, and/or genitalia)~* Participant has donated more than 500 mL of blood within the last month~* Participant has another serious disorder or illness~* Participant has suffered a serious bacterial infection (for example, pneumonia, and cellulitis) within the last 3 months~* Participant has a history of uncontrolled high blood pressure~* Participant has clinical laboratory test results at entry that are outside the normal reference range~* Participant is currently participating in or were discontinued within the last 30 days from another clinical trial involving an investigational drug~* Participant is a woman who is lactating or breast feeding~* If a participant is a woman and could become pregnant during this study, she must talk to the study doctor about the birth control that you will use to avoid getting pregnant during the study~* If a participant is post menopausal woman, she must be at least 45 years of age and have not menstruated for the last 12 months~* If a participant is a woman between 40-45 years of age, test negative for pregnancy, and have not menstruated during the last 12 months only, she must have an additional blood test to see if you can participate~* If the participant is male, he must agree to reduce the risk of female partner becoming pregnant during the study~Exclusion Criteria Specific to B:~* If a participant experienced a serious adverse event during Part A considered possibly related to ixekizumab~* If a participant experienced an adverse event during Part A that the study doctor believes continued ixekizumab treatment could cause harm to the participant.~Exclusion Criteria Specific to C:~* If a participant experienced a Serious Adverse Event during Part B considered possibly related to ixekizumab~* If a participant experienced an adverse event during Part B that the study doctor believes continued ixekizumab treatment could cause harm to the participant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg Ixekizumab (Type: EXPERIMENTAL): Part A:~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344.
- 25 mg Ixekizumab (Type: EXPERIMENTAL): Part A:~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344.
- 75 mg Ixekizumab (Type: EXPERIMENTAL): Part A:~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344.
- 150 mg Ixekizumab (Type: EXPERIMENTAL): Part A:~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.
- Placebo (Type: PLACEBO_COMPARATOR): Part A:~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344.
- 120 mg Ixekizumab (Type: EXPERIMENTAL): Part B: (optional)~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344.
- 80 mg Ixekizumab (Type: EXPERIMENTAL): Part B: (optional)~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete